SISI LI

Dr. SISI LI

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
YYYing Yao
Ying Yao
CYCong Yu
Cong Yu
YYYe Yuan
Ye Yuan
GHGuijin Huang
Guijin Huang
SLSISI LI
SISI LI

23 January 2021 in Journal of Diabetes Research
Verified
Journal Article
Open access
SLSISI LI
SISI LI
XLXuying Li
Xuying Li
XXXiangbin Xie
Xiangbin Xie
XWXiao Wei
Xiao Wei
CYCong Yu
Cong Yu
GTGuogang Tian
Guogang Tian
N-Acetylcysteine Attenuates Hyperalgesia in Rats with Diabetic Neuropathic Pain: Role of Oxidative Stress and Inflammatory Mediators and CXCR4: Objectives. CXCR4 plays critical roles in the development of diabetic neuropathic pain (DNP) in rats, and its mechanism is unknown. This study was aimed at evaluating the potential therapeutic value of the antioxidant N-acetylcysteine (NAC) against DNP in rats and how CXCR4 participates in the formation of DNP. Methods. Control or streptozotocin- (STZ-) induced diabetic Sprague-Dawley rats received vehicle or NAC for four weeks starting one week after STZ injection. Von Frey and Hargreaves Apparatus were used to analyze the behavioral changes of mechanical allodynia and heat hyperalgesia. CXCR4, p-CXCR4, interleukin- (IL-) 6, and tumor necrosis factor- (TNF-) α in the spinal cord and the prefrontal cortex were detected by western blotting. Plasma IL-6, TNF-α, superoxide dismutase- (SOD-) 1, SOD-2, and lipid peroxidation products malondialdehyde (MDA) and 15-F2t-Isoprostane were detected by ELISA. Results. The values of paw withdrawal threshold (PWT) and paw withdrawal latencies (PWL) were reduced in diabetic rats compared to control rats that were concomitant with significant increases of CXCR4, p-CXCR4, IL-6, and TNF-α protein expressions in the spinal cord and prefrontal cortex. The treatment with NAC decreased the IL-6 and TNF-α protein expression and further increased CXCR4 and p-CXCR4 in the spinal cord and the cortex of diabetic rats that were accompanied with enhancement of PWT and PWL. NAC also significantly attenuated or reverted the increases of plasma IL-6, TNF-α, SOD-1, SOD-2, MDA, and 15-F2t-Isoprostane in diabetic rats. Conclusion. It is concluded that NAC treatment could effectively alleviate DNP and that induction of CXCR4 and p-CXCR4 may represent a mechanism whereby NAC attenuates DNP.

1 June 2022 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
DRDijiao Ruan
Dijiao Ruan
YWYuanyuan Wang
Yuanyuan Wang
SLSISI LI
SISI LI
CZChao Zhang
Chao Zhang
WZWenwen Zheng
Wenwen Zheng
CYCong Yu
Cong Yu
Introduction: Nalbuphine can relieve patients’ inflammation response after surgery compared to other opioid drugs. However, its molecular mechanism has not been clear. Activation of NF-κB signaling pathway under oxidative stress and inflammation can maintain pain escalation. Methods: We firstly investigated the effect of nalbuphine on writhing test and mechanical allodynia using a rat model of inflammatory visceral pain (acetic acid (AA) administrated). Cytokines (including tumor necrosis factor (TNF)-α, Interleukin (IL)-1β, IL-2, and IL-6 in plasma were tested with ELISA technology. Expression levels of TNF-α, IκBα and p-NF-κB p65 at the spinal cord (L3–5) were measured by western blot or RT-qPCR. Results: We found that the paw withdrawal threshold (PWT) values of rats were reduced in the model group, while the numbers of writhing, levels of IL-1β, IL-2, IL-6, and TNF-α in plasma, and p-NF-κB protein and its gene expressions in the lumbar spinal cord were up-regulated. Subcutaneously injection of nalbuphine (10 μg/kg) or PDTC (NF-κB inhibitor) attenuated acetic acid-induced inflammatory pain, and this was associated with reversal of up-regulated IL-1β, IL-2, IL-6, and TNF-α in both plasma and spinal cord. Furthermore, acetic acid increased p-NF-κB and TNF-α protein levels in the white matter of the spinal cord, which was attenuated by nalbuphine. These results suggested that nalbuphine can significantly ameliorate inflammatory pain via modulating the expression of NF-κB p65 as well as inflammation factors level in the spinal cord. Conclusion: In conclusion, nalbuphine inhibits inflammation through down-regulating NF-κB pathway at the spinal cord in a rat model of inflammatory visceral pain.

6 January 2023 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
WZWenwen Zheng
Wenwen Zheng
XHXilu Huang
Xilu Huang
JWJing Wang
Jing Wang
FGFeng Gao
Feng Gao
ZCZhaowu Chai
Zhaowu Chai
CYCong Yu
Cong Yu
Background: Chronic orofacial pain is a common and incompletely defined clinical condition. The role of G protein-coupled estrogen receptor 1 (GPER1) as a new estrogen receptor in trunk and visceral pain regulation is well known. Here, we researched the role of GPER1 in the rostral ventral medulla (RVM) during chronic orofacial pain.Methods and Results: A pain model was established where rats were injected in the temporomandibular joint with complete Freund’s adjuvant (CFA) to simulate chronic orofacial pain. Following this a behavioral test was performed to establish pain threshold and results showed that the rats injected with CFA had abnormal pain in the orofacial regions. Additional Immunostaining and blot analysis indicated that microglia were activated in the RVM and GPER1 and c-Fos were significantly upregulated in the rats. Conversely, when the rats were injected with G15 (a GPER1 inhibitor) the abnormal pain the CFA rats were experiencing was alleviated and microglia activation was prevented. In addition, we found that G15 downregulated the expression of phospholipase C (PLC) and protein kinase C (PKC), inhibited the expression of GluA1, restores aberrant synaptic plasticity and reduces the overexpression of the synapse-associated proteins PSD-95 and syb-2 in the RVM of CFA rats.Conclusion: The findings indicate that GPER1 mediates chronic orofacial pain through modulation of the PLC-PKC signal pathway, sensitization of the RVM region and enhancement of neural plasticity. These results of this study therefore suggest that GPER1 may serve as a potential therapeutic target for chronic orofacial pain.

26 September 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GHGuijin Huang
Guijin Huang
YYYing Yao
Ying Yao
LFLin Fan
Lin Fan
SLSISI LI
SISI LI
Background: Previous studies have found an association between basal metabolic rate (BMR) and various malignant neoplasms, including bone tumors. BMR is also associated with bone mineral density, but the causality between BMR and benign neoplasms of bone and articular cartilage remains uncertain.Design: Single nucleotide polymorphisms (SNPs) associated with BMR (p < 5 × 10-8) were used as instrumental variables for Mendelian randomization analysis of neoplasm risk. The inverse variance weighted (IVW) method was the primary approach, with the weighted median and MR-Egger regression serving as supplements.Results: In this MR analysis, the IVW method supported a causal relationship between BMR and benign neoplasms of bone and articular cartilage (OR = 1.417; 95% CI, 1.039 to 1.930; p = 0.027). No evidence of heterogeneity or pleiotropy in the selected SNPs was found in our study. Thus, based on these results, we discovered a possible causal relationship between BMR and benign neoplasms of bone and articular cartilage.Conclusions: In this MR study, evidence suggested a genetic correlation between genetically predicted BMR and the risk of neoplasms in bone and articular cartilage.

29 June 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
JLJingyan Lyu
Jingyan Lyu
CYCong Yu
Cong Yu
SLSISI LI
SISI LI
JZJie Zeng
Jie Zeng
Objectives: The optimal intranasal sedative agent for pediatric dental procedures remains a subject of debate. We systematically reviewed and meta-analyzed head-to-head trials comparing intranasal dexmedetomidine, intranasal midazolam, oral midazolam-based regimens, and intranasal combination regimens for pediatric dental sedation. Methods: PubMed, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials were searched (2014–2025) in accordance with the PRISMA 2020 statement. The primary outcome was procedure success rate; secondary outcomes included onset time, sedation duration, satisfactory sedation rate, satisfactory behavior rate, and adverse events. Dichotomous outcomes were pooled as risk ratios (RR) and continuous outcomes as mean differences (MD), using a DerSimonian-Laird random-effects model; the certainty of evidence was rated using GRADE. All meta-analyses were performed in RevMan Web 5.4.1, with single-arm rates presented descriptively. Results: Seventeen studies involving 1,215 children aged 1–14 years met the inclusion criteria, including 15 studies randomized controlled trials (RCTs) and 2 non-randomized studies. For the primary comparison of intranasal dexmedetomidine versus intranasal midazolam, the procedure success rate showed RR of 1.29 (95% CI: 0.86, 1.94; I 2 = 68%; p = 0.22); onset time MD of 8.79 min (95% CI: 6.70, 10.87; I 2 = 83%; p < 0.00001); sedation duration MD of 20.32 min; satisfactory sedation rate RR of 1.04 (95% CI: 0.92, 1.16; I 2 = 35%; p = 0.54); and satisfactory behavior rate RR of 1.21 (95% CI: 0.94, 1.56; p = 0.14). For intranasal versus oral sedation regimens, the procedure success rate showed an RR of 1.07 (95% CI: 0.99, 1.16; p = 0.09). For combined intranasal regimens versus single intranasal agents, the procedure success rate showed RR of 1.25 (95% CI: 0.73, 2.13; p = 0.42). Risk of bias was low to moderate in most domains, with allocation concealment and blinding being the principal sources of unclear or high risk. Conclusion: Intranasal dexmedetomidine and intranasal midazolam are both clinically effective for pediatric dental sedation. Intranasal dexmedetomidine achieved a comparable procedure success rate and satisfactory sedation rate to intranasal midazolam, while demonstrating a slower onset and longer sedation duration. No statistically significant differences were detected in the procedure success rate between intranasal and oral sedation regimens or between combined and single intranasal regimens. Further adequately powered head-to-head RCTs with standardized outcome definitions are needed. Systematic review registration: https://osf.io/qc34e/ .